Načítá se...
Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations
BACKGROUND: Although management guidelines exist for several genes associated with a 2‐fold to 5‐fold increase in the relative risk for certain cancers, the value of testing for them remains controversial. METHODS: De‐identified personal and family history data for 654 individuals with pathogenic va...
Uloženo v:
| Vydáno v: | Cancer |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7003834/ https://ncbi.nlm.nih.gov/pubmed/31682005 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.32572 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|